QGEN QIAGEN N.V.

QIAGEN N.V. to release results for Q3 2024 and hold webcast

QIAGEN N.V. to release results for Q3 2024 and hold webcast

Venlo, The Netherlands, Oct. 10, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the third quarter 2024.

Press release date / time: Wednesday, November 6, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.

Conference call date / time: Thursday, November 7, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. 

Three options for joining the conference call

Register for call back connection - Click here:

Service is available 15 minutes before the call starts

Dial-in by phone

U.S.:

UK: +44 (0)330 165 3655

GER: +49 (0)69 6610 2492

Conference ID: 8002609

To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.

Access the audio webcast - Click here:

A conference call replay will be available by using the following link:

          

Contact:

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of June 30, 2024, QIAGEN employed more than 5,900 people in over 35 locations worldwide. Further information can be found at .

source: QIAGEN N.V.

category: Financial



John Gilardi
QIAGEN N.V.
 11
 

Domenica Martorana
QIAGEN N.V.
 44
 
EN
10/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on QIAGEN N.V.

 PRESS RELEASE

QIAGEN collaborates with McGill University to advance microbiome resea...

QIAGEN collaborates with McGill University to advance microbiome research QIAGEN and McGill University to collaborate on microbiome research projects to generate evidence-based knowledge for medicine and public health // McGill will serve as a beta-testing site for new QIAGEN microbiome solutions // Partnership strengthens QIAGEN’s efforts in microbiome research while supporting innovation at the McGill Centre for Microbiome Research Montreal, Canada, and Venlo, the Netherlands, Nov. 12, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collab...

Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
Oliver Metzger ... (+2)
  • Oliver Metzger
  • Stephan Wulf

Qiagen : Strong Q3 2023 results drive rise in EPS guidance

>Q3 results above our and the consensus estimates - Qiagen reported a strong set of Q3 results. Sales at CER came in at $ 502m, 1% above our ($ 495m), 2% above consensus estimates ($ 492m) and ahead of the company’s guidance of $ 495m. Y-o-y, sales increased by 5.5% despite Qiagen’s solution to gradually exit the NeuMoDx business. The company benefited predominantly from tailwind, driven by continuously strong growth of QuantiFERON (+10% to $ 122m) and QIAstat-DX (+40...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch